Hratch J. Zokian

Statistics

Publications

Citations

723

H-Index

Active since

2005

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

IRBM Science Park

United States Military Academy

Hratch J. Zokian is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

Publications per year

2005–2023

Publications

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 152 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Douglas G. Johns, Louis‐Charles Campeau, Puja Banka et al. · Circulation · 2023 · 141 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

Candice Alleyne, Rupesh P. Amin, Bhavana Bhatt et al. · Journal of Medicinal Chemistry · 2020 · 128 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9

Whitney L. Petrilli, Gregory C. Adam, Roman S. Erdmann et al. · Cell chemical biology · 2019 · 83 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +12

Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome

Xin Gu, Jasminka Dragovic, Gloria C. Koo et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

1–5 of 11